

October 2-6 • San Francisco, CA • www.idweek.org



IDWeek²⁰¹³TM

Advancing Science, Improving Care



SAVE THE DATE

A Joint Meeting of:



**Advanced
Registration
Opens for
Members**

March 2013

TB testing has evolved – has your practice?

QuantiFERON®-TB Gold



Healthcare workers are at 2- to 5-fold higher risk of developing latent tuberculosis (TB) infection compared with the general population (1).

Find out today how switching to QuantiFERON-TB Gold (QFT®) can help you improve:

- Accuracy (2, 3)
- Efficiency (2, 4)
- Cost-effectiveness (4–6)

North America ■ QIAGEN Inc ■ +1-661-775-7480 ■ customercare-us@qiagen.com



www.QuantiFERON.com

QuantiFERON-TB Gold (QFT) is CE marked. QFT is approved by the US FDA.

QFT is approved by the FDA as an *in vitro* diagnostic aid for detection of *Mycobacterium tuberculosis* infection. It uses a peptide cocktail simulating ESAT-6, CFP-10 and TB7.7(p4) proteins to stimulate cells in heparinized whole blood. Detection of IFN- γ by ELISA is used to identify *in vitro* responses to these peptide antigens that are associated with *M. tuberculosis* infection. FDA approval notes that QFT is an indirect test for *M. tuberculosis* infection (including disease) and is intended for use in conjunction with risk assessment, radiography and other medical and diagnostic evaluations. QFT Package Inserts, available in up to 25 different languages, can be found at www.QuantiFERON.com.

References: 1. Baussano, I., et al. (2011) *Emerg. Infect. Dis.* **17**, 488; 2. QFT Package Insert, July 2011, US05990301K; 3. Vinton, P., et al. (2009) *Infect. Control Hosp. Epidemiol.* **30**, 215; 4. De Perio, M., et al. (2009) *Arch. Intern. Med.* **169**, 179; 5. Nienhaus, A., et al. (2008) *Int. Arch. Occup. Environ. Health* **81**, 295; 6. Nienhaus, A., et al. (2011) *BMC Health Serv. Res.* **11**, 247. Trademarks: